San Diego, CA – Metacrine, Inc., a leading and innovative biotechnology company focused on drug development for metabolic diseases, announced it will present two abstracts on its novel FXR agonist program at the upcoming International Liver Congress Meeting of the European Association for the Study of Liver Disease (EASL) in Amsterdam, Netherlands. Metacrine has developed a leading and comprehensive FXR agonist program based on a unique non-bile acid chemical scaffold.
The first abstract (PS-027), titled “FXR agonists with sustained systemic rather than transient intestinal exposure are more efficacious in a diet-induced obese non-alcoholic steatohepatitis mouse model” will be presented as an oral platform presentation on Thursday, April 20th, 2017 at 5pm.
The second abstract (FRI-361), titled “M480, a novel non-bile acid FXR agonist, shows improvement across multiple parameters in a diet-induced obese mouse model with biopsy-confirmed NASH” will be part of the poster session on Friday, April 21st, 2017.
“FXR represents a foundational and clinically validated target for non-alcoholic steatohepatitis,” said Ken Song, MD, President and CEO of Metacrine. “Metacrine’s differentiated FXR agonist program can position us with the best-in-class molecule.”
Metacrine is a privately held biotechnology company headquartered in San Diego, CA. The company is focused on efficiently developing innovative drugs that materially benefit patients with metabolic disease.